Samia Arifi

Publications

• Research Article   
  Efficacy and Tolerability of CDK4/6 Inhibitors in Patients with HR+/HER2â?? Metastatic Breast Cancer: Real-World Data
  Author(s): Abir Oufrid*, Basma Aabboub, Diango Keita, Sara Nejjari, Samia El Hakym, Hafssa El Hilali, Chaymae Chbihi, Lamiae Amaadour, Karima Oualla, Zineb Benbrahim, Samia Arifi and Nawfel Mellas
  
  Introduction: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, in combination with hormone therapy, are currently the standard treatment for hormone receptor–positive, HER2-negative (HR+/HER2−) metastatic breast cancer. Although their efficacy has been demonstrated in randomized clinical trials, real-world data remain limited, particularly in populations underrepresented in pivotal studies. The objective of this study was to evaluate, in a real-world setting, the efficacy and Tolerability of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer. Methods: This was a retrospective study of patients admitted to the medical oncology department at CHU HASSAN II Hospital in Fès, who received CDK4/6 inhibitors for HR+/HER2− metastatic breast cancer over a six- Year period, from 2018 to 2023, regardless of the date of their f.. Read More»
  

  Abstract HTML PDF